/News

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

By | September 14th, 2020|Generics, News|

Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of Directors

By | September 8th, 2020|Generics, News|

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

By | September 8th, 2020|Generics, News|

Cycle Pharmaceuticals Secures $25 Million Debt Financing

By | September 5th, 2020|Generics, News|

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

By | August 5th, 2020|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

By | May 13th, 2020|News, Nityr|

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

By | May 5th, 2020|News, Nityr|

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

By | April 19th, 2020|News, Resource|

Cycle Pharmaceuticals’ Supply Chain update

By | March 13th, 2020|News, Resource|

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

By | December 18th, 2019|News, Nityr|